Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Globus Medical ( (GMED) ) has issued an announcement.
On March 23, 2026, Globus Medical announced that board member John A. DeFord, Ph.D., resigned from its Board of Directors effective immediately and will not stand for re-election at the June 3, 2026, annual shareholders’ meeting. The company emphasized there was no disagreement behind his departure and highlighted his contributions during the NuVasive merger and his service on the Nominating and Governance Committee, signaling continuity in governance despite the leadership change.
Chairman David C. Paul praised DeFord’s role in supporting Globus Medical’s growth as a leader in musculoskeletal technology, while DeFord described his board tenure as a privilege. The orderly nature of his exit and the company’s public recognition of his impact suggest a stable transition for investors and other stakeholders, even as the board prepares to adjust its composition.
The most recent analyst rating on (GMED) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Globus Medical stock, see the GMED Stock Forecast page.
Spark’s Take on GMED Stock
According to Spark, TipRanks’ AI Analyst, GMED is a Outperform.
GMED scores well on financial strength and cash generation, reinforced by a positive earnings-call setup with reaffirmed revenue guidance and raised EPS expectations. Technicals support the trend (price above major moving averages), while the main constraint is valuation (P/E ~29.7) alongside execution/lumpiness risks noted in guidance and integration commentary.
To see Spark’s full report on GMED stock, click here.
More about Globus Medical
Globus Medical, Inc. is a global musculoskeletal solutions company that develops technologies across spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The company focuses on addressing unmet clinical needs while providing education and clinical support to drive adoption of its musculoskeletal innovations worldwide.
Average Trading Volume: 1,254,084
Technical Sentiment Signal: Buy
Current Market Cap: $11.65B
Find detailed analytics on GMED stock on TipRanks’ Stock Analysis page.